ANL - Multiplikator Forward P/S Adlai Nortye Limited

Lambang korporat lan logo Adlai Nortye Ltd (ANL)

Original drug sales in China generate steady revenue for Adlai Nortye Ltd. (ANL), supporting a forward price-to-sales ratio where the metric value stands at 32.60. The executive team combines global expertise and commercial calculation to drive biotech expansion. The recruitment of top specialists is secured through a bonus system and strict KPIs, stimulating the development of innovative anti-tumor agents.

Adlai Nortye Limited - Rasio kapitalisasi marang dodolan sing dikarepake ANL (periode 13.04.2026 - 17.11.2026)

Adlai Nortye Ltd - rincian analitis lan metrik utama (ANL)

- rega pasar lan target rega analis:
Analisis wiwitan perusahaan:ANL (Adlai Nortye)
Produk asli Adlai Nortye

The forward P/S ratio determines the market value of Adlai Nortye Ltd. (ANL) relative to expected revenue, making it possible to identify hidden business vulnerabilities ahead of a potential acquisition. The current value of 32.60 within the forward P/S valuation serves as a stress-testing tool, confirming the asset's investment attractiveness through patent protection and the expanding application of antineoplastic drugs in the US and China.

Pesaing wigati

Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tuhurabio.com HURA|Multiplikator Forward P/S TARA|FATE: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX (TScan) - Rega mangsa ngarep marang pendapatan|Champions Oncology, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake XBiotech Inc XBIT|CVM: Multiplikator Forward P/S|OSTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Multiplikator Forward P/S artivabio.com|Rasio rega marang prakiraan pendapatan Veru Pharma (VERU)|Multiplikator Forward P/S Tempest Tx (TPST)|Rasio rega marang prakiraan pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang prakiraan pendapatan|Mural Oncology - Multiplikator Forward P/S|KAPA - Multiplikator Forward P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CytoMed|Rasio rega marang prakiraan pendapatan curis.com|Multiplikator forward rega marang pendapatan Apollomics, Inc. (APLM)|Multiplikator Forward P/S THAR|Advanced Biomed Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Genprex GNPX|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S